Pfizer, Inc. vs Genentech, Inc.

FINAL WRITTEN DECISION 35 U.S.C. § 318(a) and 37 C.F.R. § 42.73 AND RELATED ORDERS

Decision Institution of Inter Partes Review and Grant of Motion for Joinder

Second Updated Mandatory Notices

Decision - Petitioner's Motions for Pro Hac Vice Admission of Sarah K. Tsou, Benjamin A. Lasky, Christopher J. Citro, and Mark C. McLennan

Petitioners Updated Mandatory Notices

PO Preliminary Response

Lipton Deposition Transcript

Petitioner's Updated Mandatory Notices

Petitioner's Motion for the PHV Admission of Benjamin A. Lasky

Petitioner's Motion for the PHV Admission of Mark C. McLennan

Declaration in Support of Motion for the PHV Admission of Mark McLennan

Petitioner's Motion for the PHV Admission of Christopher J. Citro

Declaration in Support of Motion for the PHV Admission of Christopher J. Citro

Petitioner's Motion for the PHV Admission of Sarah K. Tsou

Petitioner's Updated Power of Attorney

Declaration in Support of Motion for the PHV Admission of Benjamin A. Lasky

Petitioner's First Amended Appendix of Exhibits

Declaration in Support of Motion for the PHV Admission of Sarah K. Tsou

Patent Owner's Updated Mandatory Notices

Petitioner's Updated Mandatory Notices

Order Conduct of the Proceeding

Petitioner's Reply In Further Support Of Motion For Joinder

Petitioner¿¿¿s Updated Mandatory Notices

Patent Owner's Opposition to Motion for Joinder

Notice of Accord Filing Date

Notice of Joint Stipulation Regarding Joinder with IPR2017-01121

Genentech's Power of Attorney

Patent Owner's Mandatory Notices

Petitioner's Motion for Joinder Under 35 U.S.C. 315(c), 37 C.F.R. 42.22, AND 42.122(b)

Antibody to HER 2 neu Receptor Blocks DNA Repair After Cisplatin in Human Breast and Ovarian Cancer Cells (Pietras1994).

Anti HER2 Humanized Monoclonal Antibody (MAb) Alone and in Combination with Chemotherapy Against Human Breast Xenografts (Baselga Mar. 1994).

Exhibit 1129 Miller (1981)

Petitioner's Power of Attorney

Petition for Inter Partes Review of U.S. Patent No. 7,846,441

U.S. Patent 7,846,441

Allan Lipton, M.D., curriculum vitae

U.S. Patent 7,846,441 File History, Vol. 1

U.S. Patent 7,846,441 File History, Vol. 2

U.S. Patent 7,846,441 File History, Vol. 3

U.S. Patent 7,846,441 File History, Vol. 4

U.S. Patent 7,846,441 File History, Vol. 5

U.S. Patent 7,846,441 File History, Vol. 6

U.S. Patent 7,846,441 File History, Vol. 7

U.S. Patent 7,846,441 File History, Vol. 8

U.S. Patent 7,846,441 File History, Vol. 9

Declaration of Allan Lipton, M.D.

U.S. Patent 7,846,441 File History , Vol. 10

MOLECULAR BIOLOGY OF THE CELL (Bruce 1994)

Excerpts from CANCER PRINCIPLES & PRACTICE OF ONCOLOGY (DeVita and Lippincott 1993)

New Chemotherapeutic Agents for Breast Cancer (Abrams Aug. 1994)

Declaration of Susan D. Hellmann (Dec. 10, 1998)

Declaration of Mark X. Sliwkowski (Dec. 10, 1998)

Memorial Sloan Kettering Cancer Center Experience with Paclitaxel in the Treatment of Breast Cancer (Seidman Oct. 1995).

Over Expression and Clinical Taxane Sensitivity A Multivariate Analysis in Patients with Metastatic Breast Cancer (Seidman Mar. 1996).

Taxol (Paclitaxel) for Injection Concentrate

Paclitaxel Couplets with Cyclophosphamide or Cisplatin in Metastatic Breast Cancer (Tocher Feb. 1996).

Phase I/II Trial of Biweekly Paclitaxel and Cisplatin in the Treatment of Metastatic Breast Cancer (Gelmon Apr. 1996).

"Excerpts from CLINICAL ONCOLOGY (Martin D. Abeloff et al., eds.,New York Churchill Livingstone, 1995)."

"Inhibitory Effects of Combinations of HER 2 neu Antibody and Chemotherapeutic Agents Used for Treatment of Human Breast Cancers (Pegram 1999)."

Biweekly Paclitaxel (Taxel) and Cisplatin in Breast and Ovarian Breast Cancer (Gelmon Oct. 1994).

Phase II Study of Weekly Intravenous Recombinant Humanized Anti p185HER2 Monoclonal Antibody in Patients with HER2 neu Overexpressing Metastatic Breast Cancer (Baselga Mar. 1996).

Antitumor Activity of Paclitaxel in Combination with Anti-growth Factor Receptor Monoclonal Antibodies in Breast Cancer Xenografts (Baselga Mar. 1994).

Phase II Study of Intravenous Recombinant Humanized Anti p185 HER2 Monoclonal Antibody (rhuMAB HER2) Plus Cisplatin in Patients with HER2 NEU Overexpressing Metastatic Breast Cancer (Pegram Mar. 1995).

Outcomes of Cancer Treatment for Technology Assessment and Cancer Treatment Guidelines (Feb.1996).

Paclitaxel (Taxol) in Breast Cancer (Arbuck Feb. 1994).

Cross Resistance and Collateral Sensitivity Studies in Cancer Chemotherapy (Hutchison 1963).

Exhibit 1126 Fiebig (1984)

Exhibit 1127 Sorenson (1990)

Exhibit 1128 Mattern (1988)